MedTrace Logo

Multidimensional Characterization of Dyspnea in Children

NCT05500833 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 400

Last updated 2025-12-09

No results posted yet for this study

Summary

There is no specific tool existing to describe dyspnea in children in a multidimensional way.

It has been shown in adult studies that multidimensional dyspnea evaluation scales are well correlated to quality of life and respiratory function impairments.

The investigators hypothesis is that using multidimensional dyspnea evaluation scales could allow for a more systematic and precise evaluation of this symptom in children, thus improving management and follow-up of patients presenting with acute (asthma attack, infectious diseases) and chronic (cystic fibrosis, primary ciliary diskynesia, neuromuscular diseases) respiratory insufficiency.

Conditions

  • Dyspnea and Respiratory Insufficiency in Children

Interventions

OTHER

Multidimentional observation scale (MDP)

Upon arriving to the hospital (for an hospitalization or a consultation), a trained and declared investigator will inform the patients and their parents of the study, orally and using a written information note. Participation to the study will also be proposed to under aged children in an adequate language and a specific information note will be handed to them. If they wish, they will have a 20 min reflexion time before deciding on participating to the study.One the patient is included, the study will unfold as follows. First, Evaluation of acute dyspnea: general data and dyspnea scores will be collected upon inclusion, and dyspnea score will be collected once again 30 min later, and subsequently one a day until the end of hospitalization (test-retest). Data from clinical examination and treatment modifications will also be collected daily. Second, Evaluation of chronic dyspnea: general data and dyspnea scores will be collected upon inclusion and 1 to 1.5h later

Sponsors & Collaborators

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Eligibility

Min Age
6 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-26
Primary Completion
2028-02-26
Completion
2028-02-26

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05500833 on ClinicalTrials.gov